Primary Open-angle Glaucoma Clinical Trial
Official title:
An Educational Intervention to Increase Adoption of Selective Laser Trabeculoplasty as First-Line Treatment for Glaucoma
The purpose of this study is to develop an educational program that will help improve the patients' understanding of what laser treatment is, how it might be beneficial to them, and why it should be the first eye pressure lowering glaucoma treatment to consider before the use of glaucoma eye drops.
Glaucoma is a disease characterized by optic nerve damage, visual field defects, elevated
intraocular pressure (IOP) and progressive vision loss. More than 3 million Americans have
glaucoma and more than 150,000 are blind as a result.
Regular use of glaucoma medications can usually lower intraocular pressure (IOP), prevent
disease progression, preserve vision and prevent blindness. However, many people with
glaucoma do not always use their medication as directed, with about one-third to one-half of
patients with glaucoma not taking their drops as often as necessary, or have difficulty
putting in the drops. There are also numerous local side effects from using glaucoma eye
drops including red eyes, blurry vision and dry eye symptoms. Systemic side effects from eye
drops range from triggering asthma, to lethargy and depression.
Selective laser trabeculoplasty (SLT) has been used safely and effectively for the treatment
of elevated IOP in patients with open angle glaucoma for more than 20 years. SLT may result
in mild and temporary IOP elevation, but this is a small risk and rarely significant. Other
side effects include blurred vison and inflammation of the cornea (front, clear part of the
eye), but they are extremely rare.
The purpose of this study is to develop an educational program that will help improve the
patients' understanding of what laser treatment is, how it might be beneficial to them, and
why it should be considered as first glaucoma treatment before the use of glaucoma eye drops.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01841437 -
Glaukos® iStent® Trabecular Micro-Bypass Stent System In Conjunction With Cataract Surgery Postmarket Registry
|
N/A | |
Completed |
NCT02077231 -
Study of Vitamin A and Carbomer in Comforting the Ocular Surface Irritations of Glaucoma Patients
|
N/A | |
Completed |
NCT01410188 -
Safety/Efficacy Study: OPA-6566 Ophthalmic Solution in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension
|
Phase 1/Phase 2 | |
Recruiting |
NCT05557058 -
GORE Glaucoma Drainage Implant Clinical Study
|
N/A | |
Not yet recruiting |
NCT03924544 -
Decorin in Sub Scleral Trabeculectomy
|
Phase 1 | |
Active, not recruiting |
NCT03673644 -
Impact of Glaucoma and Visual Field Loss on Life Space
|
||
Completed |
NCT01915940 -
Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension
|
Phase 2 | |
Completed |
NCT03889652 -
Optical Coherence Tomography of Nerve Fiber Layer and Ganglion Cell Complex After Cataract Extraction
|
||
Terminated |
NCT03273907 -
Post Approval Study of the CyPass System
|
N/A | |
Recruiting |
NCT03193333 -
PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma (PRO-122LATAM)
|
Phase 3 | |
Recruiting |
NCT03921931 -
Retinal Photoreceptor Outer Segment Length Before and After Light Stimulation - a Pilot Study
|
N/A | |
Not yet recruiting |
NCT04609345 -
Prevalence of Ocular Surface Disease in Malaysian Glaucoma Patients
|
||
Recruiting |
NCT05264818 -
Assessment of Endothelial Glycocalyx in Patients With Primary Open-angle Glaucoma
|
||
Completed |
NCT04333433 -
PRESERFLO® MicroShunt Extension Study
|
||
Enrolling by invitation |
NCT02144103 -
Effectiveness and Safety of Adipose-Derived Regenerative Cells for Treatment of Glaucomatous Neurodegeneration
|
Phase 1/Phase 2 | |
Completed |
NCT01281020 -
Adherence With Fixed Versus Unfixed Glaucoma Therapy
|
||
Recruiting |
NCT04891588 -
Switching From the Preserved to the Preservative - Free Latanoprost - Timolol FC in Glaucoma Patients With OSD
|
N/A | |
Completed |
NCT03145129 -
PAIR Study-PAP And IOP Relationship: Study 2
|
||
Completed |
NCT03104621 -
Efficacy and Tolerability of Preservative-free 0.0015% Tafluprost in Glaucoma Patients
|
Phase 4 | |
Completed |
NCT01742104 -
Multicentric Observational Study on Quality of Life in Glaucoma
|
N/A |